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Abstract
Background—Outcome of low-grade glioma (LGG, WHO grade II) is highly variable reflecting 
molecular heterogeneity of the disease. We compared two different single modality treatment 
strategies: standard radiotherapy (RT) versus primary temozolomide (TMZ) chemotherapy with 
the aim of tailoring treatment and identifying predictive molecular factors.
Methods—477 patients (2005 – 2012, median FU 48 months) with a low-grade glioma 
(astrocytoma, oligoastrocytoma, oligodendroglioma, WHO grade II) with at least one high-risk 
feature (age > 40 years, progressive disease, tumor > 5 cm or crossing the midline, neurological 
symptoms (e.g. focal or mental deficits, increased intracranial pressure or intractable seizures)) 
were, after stratification by chromosome 1p-status, randomized to either conformal RT (50.4 
Gy/28 fractions) or dose-dense TMZ (75 mg/m2 daily × 21 days, q28 days, max. 12 cycles). 
Random treatment allocation was performed online using a minimization technique. A planned 
analysis was performed after 246 progression events. All analyses are intent to treat. Primary 
clinical endpoint was progression-free survival (PFS), correlative analyses included molecular 
markers (1p/19q co-deletion, MGMT methylation status, IDH1+2 mutations). The trial has been 
registered at the European Trials Registry (EudraCT 2004-002714-11) and at ClinicalTrials.gov 
(NCT00182819).
Findings—Four hundred seventy-seven patients were randomized. Severe hematological toxicity 
occurred in 14% of TMZ-treated patients, infections in 3% of TMZ-treated patients, and 1% of 
RT-treated patients. Moderate to severe fatigue was recorded in 3% of patients in the RT group and 
7% in the TMZ group.
At a median follow-up of 48 months (IQR:31–56), median PFS was 39 months (IQR:16–46) in the 
TMZ arm and 46 months (IQR:19–48) in the RT group (hazard ratio 1.16, 95% CI, 0.9–1.5; 
p=0.22). Median OS has not been reached. Exploratory analyses identified treatment-dependent 
variation in outcome of molecular LGG subgroups (n=318).
Interpretation—There was no significant difference in outcome of the overall patient population 
treated with either radiotherapy alone or TMZ chemotherapy alone. Further data maturation is 
needed for overall survival analyses and evaluation of the full predictive impact of the molecular 
subtypes for individualized treatment choices.
Funding—Merck & Co, Swiss-Bridge Award 2011, Swiss Cancer League.
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Research in context
Evidence before this study
Management of patients suffering from low grade glioma (LGG, WHO grade II) has been 
based mainly on clinical prognostic factors. Median survival is highly variable from 3.2 
(high-risk disease) to 7.8 years (low risk), with a large range within each clinical subgroup. 
Known favorable molecular prognostic factors comprise co-deletion of chromosome 1p/19q, 
and more recently mutation of isocitrate dehydrogenase 1 or 2 (IDH1/2) that was discovered 
to be present in most LGG (>80%). The optimal treatment modality and sequence of LGG 
patients is highly controversial, aiming at balancing a favorable effect on progression-free 
survival versus long-term toxicity in this overall young patient population (median <45 
years). We searched PubMed between June 1993 and April 2016 using the search terms, 
“randomized” “low grade glioma” “chemotherapy” “radiotherapy” and identified a total of 
only 4 conclusive trials, including reports on delaying treatment initiation, or the optimal 
dose of radiotherapy (EORTC 22844; EORTC 22845/MRC BR04; NCCTG/RTOG/ECOG; 
RTOG9802). The most recent report of RTOG 9802 demonstrates an impressive 5.5-year 
improvement in median overall survival when up to 6 cycles of adjuvant PCV-chemotherapy 
(procarbazine, CCNU, vincristine) were added after standard RT. However, no data is 
available on the prognostically highly relevant molecular subtype displaying 1p/19q co-
deletion. The lack of this molecular information and the availability of less toxic drugs 
encumber the translation into clinical practice.
Added value of this study
Our study aimed after central histological confirmation at molecular characterization, and 
stratification before randomization, and we thus have tumor tissue available for most 
patients. It is the largest trial of prospectively treated patients allowing for molecular tumor 
characterization and correlation with outcome. Although overall, no significant difference in 
outcome (PFS) could be demonstrated, it demonstrates the value of molecular 
characterization and subgrouping of the disease. Patients with an IDH mutation without co-
deletion of 1p/19q, displayed a significantly longer PFS when treated with RT, while 
patients with wild type IDH belong to different categories of glioma often with a much more 
aggressive course.
Implications of all the available evidence
This is first study in the era of modern and molecular neuro-oncology that successfully 
achieved its recruitment goal. The availability of tumor tissue from most patients allowed for 
confirming the prognostic value of recently identified molecular subgroups that are now an 
integral part of the WHO classification of LGG. For future clinical trials, treatment strategies 
shall be adapted to the risk of tumor progression or recurrence. Ultimately this should lead 
individually and risk-adapted customized treatments. Most patients with a low-grade glioma 
without mutation of IDH1/2 fare substantially worse under either single modality treatment. 
Wild-type IDH1/2 tumors may molecularly be attributed to other tumor entities including 
indolent tumors such as pilocytic astrocytoma, or most frequently to different subtypes of 
glioblastoma. The latter patients may benefit from a more intensive combined modality 
approach. Similarly, patients with IDH mutated tumors without 1p/19q co-deletion are best 
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to be treated with radiotherapy and derive little benefit from chemotherapy (be it PCV or 
TMZ). On the other hand, patients with co-deleted tumors carry the best prognosis, and may 
benefit from adjuvant chemotherapy after irradiation; whether treatment with chemotherapy 
alone is as effective will require further maturation of the data of the current trial.
Ongoing exploratory analyses may allow for identifying putative predictive molecular 
markers for further refinement of the prognostic value of the molecular subtyping, and 
importantly may identify novel therapeutic targets.
Introduction
Low-grade glioma (LGG) encompasses a diverse group of diffusely infiltrative, slowly 
growing glial brain tumors. They frequently affect adults in their third or fourth decade of 
life. The natural history varies greatly and optimal management remains controversial. 
Treatment options include watchful waiting, radical surgery, radiotherapy, chemotherapy or 
a combination thereof.1 Individual management decisions depend on clinical and molecular 
prognostic factors, extent of symptoms, estimated risk of malignant transformation, and risk 
of acute and late treatment-associated toxicity. We previously derived a prognostic score 
with estimated median survival times varying from 3.2 to 7.8 years. Age ≥ 40 years, 
astrocytic histology, tumor size ≥ 6 cm, tumors crossing the midline and presence of 
neurological deficits were associated with an inferior prognosis.2 More recently, molecular 
characteristics particularly co-deletion of chromosomal arms 1p/19q (codel) that are 
associated with oligodendroglial histology and mutations of isocitrate dehydrogenase (IDH) 
1 or 2 genes (IDHmt) have been associated with a more favorable prognosis and better 
response to both chemotherapy and radiation.3,4
Radiation therapy (RT) has been the accepted standard treatment for progressive and 
inoperable LGG for over 3 decades, established at a time when neither modern imaging 
technology nor alternative treatment modalities were available.2,5–8 Temozolomide (TMZ), 
an alkylating agent was specifically developed with chemical properties to cross the blood-
brain-barrier, and it was first approved for the treatment of recurrent anaplastic astrocytoma 
in 1999. Exquisite sensitivity to chemotherapy had been demonstrated for 
oligodendroglioma with 1p/19q co-deletion, and uncontrolled trials suggested activity of 
TMZ also against LGG.9–12 Dose-dense regimens allowing for increased doses and 
prolonged exposure were considered conceptually attractive in particular for slow 
proliferating tumors like LGG.13–15 We addressed the question whether initial TMZ 
chemotherapy confers an advantage in outcome compared to standard RT aiming at 
prolonging time to progression, reduction in long-term toxicity and better quality of life. An 
equally important secondary objective was to identify molecular predictive factors, thus 
allowing tailoring treatment decisions based on individual tumor characteristics.
Methods
Study design and participants
This prospective randomized phase III study was comprised of 2 steps, an initial registration 
step at any time after initial diagnosis, allowing for tissue collection and molecular analyses 
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required for stratification; and a randomization step at the time point when treatment was 
considered clinically indicated.
Adult patients (age ≥ 18 years) with histologically confirmed supratentorial diffusely 
infiltrating WHO grade II gliomas (astrocytoma, oligoastrocytoma and oligodendroglioma) 
were eligible for the study. Availability of paraffin-embedded tumor tissue, and a heparin 
blood sample was required for central pathology review and molecular testing for 1p. For 
patients with a substantial interval between initial tissue diagnosis and treatment start, 
confirmation of the histology by repeat biopsy was recommended. Patients whose tumour 
had transformed into a higher grade were excluded. Before randomization (2nd step) a 
separate informed consent was obtained. To be eligible for step 2, patients had to require 
active treatment other than surgery, defined by at least one of the following criteria: (1) age ≥ 
40 years, (2) radiologic tumor progression, (3) new or worsening symptoms and (4) 
refractory seizures. Other eligibility criteria included: WHO performance status ≤ 2, 
Radiation Therapy Oncology Group (RTOG) neurological function score of 0–3, adequate 
hematologic, renal, and hepatic function (absolute neutrophil count, ≥1500/mm3; platelet 
count, ≥100,000/mm3; serum creatinine level ≤1.5 times the upper limit of normal (ULN); 
total serum bilirubin level ≤1.5 times ULN; and liver-function values <2.5 times ULN), 
results of genetic testing available and not candidate for treatment exclusively by surgery. 
Patients who had received prior chemotherapy or RT were excluded.
Organization of the trial
The trial was developed by the principal investigators in collaboration with the investigators 
from the participating groups and the EORTC Headquarters. All data were reviewed by 
EORTC collaborators and Drs. Stupp or Baumert, where appropriate. Statistical analyses 
were performed by Thierry Gorlia, PhD. Translational research and molecular marker 
evaluation were coordinated by Monika E. Hegi, PhD.
Trial sponsors were EORTC (22033/22036) in Europe, (some responsibilities delegated to 
the Medical Research Council Clinical Trial Unit (MRC-CTU) in the UK (BR13)), the 
NCIC Clinical Trials Group (NCIC CTG) in Canada (CE.5), and the Tasman Radiation 
Oncology Group (TROG) in Australia. The protocol was approved by the ethics committees 
and competent authorities of all participating centers and countries. All patients gave written 
informed consent for pathology review and molecular testing, and participation in the trial.
Randomisation and masking—Patients were stratified before randomization according 
to World Health Association (WHO) performance status (0 or 1 versus 2), age (<40 vs ≥ 40 
years), presence of contrast enhancement on magnetic resonance tomography (MRI), the 1p 
status (deleted versus normal versus indeterminate) and the treating medical center. 
Randomization was performed online by the European Organisation for Research and 
Treatment of Cancer (EORTC) using a minimization technique. A minimization technique 
was used for random treatment allocation with prospective stratification by institution, 1p 
deletion (yes/no/undetermined), contrast enhancement (yes/no), age (<40/≥40 years), WHO 
performance status (0 or ≥1). The assigned treatment had to begin within six weeks after 
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randomization. By the nature of the intervention, the trial was open-labeled and both 
patients, treating physicians and researchers were aware of the assigned intervention.
Procedures
Standard treatment consisted of 3D-conformal RT up to 50.4 Gy (28 × 1.8 Gy daily, 5 days 
per week over a period of 5–6 weeks). Intensity-modulated and stereotactically-guided RT 
was allowed if same dose prescription as for non-stereotactic RT was used. RT treatment 
volumes were defined based on T2 or FLAIR magnetic resonance imaging (MRI). In case of 
tumor resection, postoperative imaging was used. All participating sites had to comply with 
an extensive quality assurance program including dosimetry, dummy run and individual 
patient radiotherapy plan review (level III).16–18
Patients randomized to the experimental arm were to receive TMZ (Temodal®, Temodar®, 
Merck & Co, White House Station, NJ) in a dose-dense schedule of 75 mg/m2 per day for 21 
days, repeated every 28 days for up to 12 cycles, or until tumor progression or unacceptable 
toxicity. Antibiotic prophylaxis against opportunistic Pneumocystis jiroveci infections was 
recommended for lymphocyte counts < 500/mm3. Anti-emetic prophylaxis was administered 
at the local investigators’ discretion.
The baseline evaluation (within 6 weeks prior to randomization) included MRI, a health-
related quality-of-life questionnaire (EORTC QLQ-30 and Brain Cancer ModuleBN-20), 
full clinical and neurological evaluation including assessment of seizure frequency (if 
applicable), as well as complete blood counts and blood chemistry. The extent of tumor 
resection was assessed by the neurosurgeon per local practice based on postoperative 
imaging. All patients were evaluated clinically and neurologically every 3 months including 
quality of life, tumor assessment with MRI was performed every 6 months. Radiological 
progression was defined as an increase of 25% in bi-dimensional perpendicular product of 
signal hyperintensity on MRI T2 weighted images, or appearance of an area of new contrast 
enhancement, or a 25% increase in contrast enhancement on T1 weighted MR images with 
or without an increase in the area of T2-weighted signal hyperintensity. Clinical progression 
was defined as deterioration due to increasing neurological signs or symptoms with no other 
explanation or deterioration of WHO performance status or RTOG neurologic function. 
Quality of life results will be reported separately.
Pathology review and molecular testing was performed centrally (AvD; CH, DC, SK, JMK; 
JPR for Canada). Deletion of chromosomal arms 1p and 19q was tested by microsatellite 
markers or using FISH as described.19,20 The mutation status of IDH1 and 2 was determined 
by immunohistochemistry for the most common mutation IDH1-R132H, complemented by 
DNA sequencing of negative cases.21 The MGMT promoter methylation status was 
determined by the MGMT-STP27 model.22,23
Outcomes
The primary endpoint was progression-free survival (PFS) defined as the time between the 
date of randomization and the date of clinical or radiological progression or death. 
Secondary and translational endpoints were overall survival (OS), quality-of-life, mini-
mental state examination (MMSE) and the association of molecular markers with outcome. 
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Markers pre-specified in the protocol comprised 1p/19q status, and MGMT promotor 
methylation status (amended protocol version 2.2, October 2007). The IDH1/2 mutations in 
glioma have been published in 2009 and were included subsequently.4,24
Statistical analysis
Observation of 216 PFS events among the 466 randomized patients are needed for an 80% 
power and a significance level of 5% (two-sided) in order to detect a 13% increase in 5-year 
progression-free survival rate i.e. from 45% in the RT arm to 58%, corresponding to a 
treatment hazard ratio for progression (HR) equal to 0.68. Estimated PFS is calculated 
according to Kaplan–Meier from the date of randomization until event; for comparison a 2-
sided log-rank test at 5% significance was used. All analyses were conducted on an 
intention-to-treat basis. A Cox model with the treatment as only variable was fitted to 
measure unadjusted treatment effect (HR). For sensitivity analysis, HR was also computed 
adjusted by the stratification factors (1p deleted versus 1p normal versus undeterminable; 
contrast enhancement, +/− contrast on MRI; age, <40 years versus ≥40 years; WHO 
performance status, 0 or 1 versus 2) and other possible confounding factors — tumor 
crossing the midline (No/Yes), and baseline RTOG neurological function score (0,1,2,3,4). 
The markers’ predictive effect was assessed by logrank interaction test. Markers prognostic 
value was assessed by Kaplan–Meier, log-rank test and Cox models (to measure HR) 
stratified by the treatment. These exploratory analyses were performed at 5% significance 
level. No proportionality of hazards assumptions check was planned by the protocol. The 
relationship between IDHmt and the extent of primary resection (biopsy versus partial 
resection versus total resection) was tested with the Cochran-Armitage Trend Test. 
Treatment duration was different between the 2 arms, and adverse effects are reported 
separately for the duration of TMZ chemotherapy (over 1 year) and for the duration of 
radiotherapy, defined as day 1 of RT until 28 days after the last administration of RT. All 
statistical analyses were done using SAS version 9.4. For this analysis a clinical cut-off date 
of 17. January was used and the database was locked on 7. August 2013.
Role of the funding source
The trial was supported by an unrestricted educational grant and free supply of TMZ by 
Merck & Co (formerly Schering-Plough). The drug manufacturer was neither involved in the 
trial design nor analysis. Translational research was funded in part by the Swiss Cancer 
League and the Swiss Bridge Award (to MEH). The corresponding author, MEH and RS had 
full access to all of the data and the final responsibility to submit for publication.
The study was registered at EudraCT#2004-002714-11 and ClinicalTrials.gov 
NCT#00182819, and was performed according to the declaration of Helsinki. The trial 
completed its enrollment, patients continue to be followed as per protocol.
Results
From September 23, 2005 until March 26, 2010, 707 patients (78 institutions/19 countries) 
were registered, and from December 6, 2005 until December 21, 2012 477 patients were 
randomized to receive either RT (n=240) or TMZ (n=237, figure 1). Twelve institutions 
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randomized about half of the patients. The patient characteristics were well balanced with a 
median age of 45 years, 189/477 (40%) had undergone a diagnostic biopsy only, 206/477 
(43%) a partial tumor debulking and in 81/477(17%) the surgeon considered the resection to 
be complete (table 1). The institutional diagnosis of a WHO grade II glioma was confirmed 
in 438/477 tumor samples (92%). The diagnosis of the histologic subtypes, astrocytoma, 
oligodendroglioma, or oligoastrocytoma, and tumor grade revealed poor interobserver 
agreement between the local and central, as well as the two central pathologists with kappa 
values between 0.3 and 0.4 (see appendix of supplemental data, appendix table S1 and figure 
S1).
Treatment could be administered in both arms at the planned intensity and without undue 
major interruptions or delays in most patients. Ninety-one percent of the patients completed 
RT as planned, 75% completed 12 cycles of TMZ chemotherapy (range 1–14), 4 patients 
(1.8%) continued TMZ for more than 12 cycles for unspecified reasons. In the TMZ arm, 21 
patients (9%) discontinued treatment due to progression, 18 patients (8%) due to toxicity, 
and 8 (3%) for other reasons. A total of 34/232 patients (154%) had at least one dose 
reduction due to haematotoxicity in 19 patients (8%), non-haematological toxicity in 9 (4%) 
patients and for other reasons in 11 patients (5%, in some patients multiple reasons). Two 
patients were reported to have died several months after the end of treatment possibly due to 
complications of the therapy; one in the RT arm due to encephalopathy and progressive 
disease and one due to bone marrow failure in the TMZ arm (Appendix table S2).
Overall, grade 3 / 4 hematological toxicity was observed in 13.7% (n=32) patients in the 
TMZ group (table S2). Infections were reported in 2 patients during RT (0.9%), and in 8 
patients while on TMZ therapy (3.4%), including 2 patients with Pneumocystis jiroveci 
pneumonia (1 in each treatment arm). The most common non-hematologic adverse events 
were neurologic – (i.e. sensory deficits, mood alteration, ischemia, seizures and 
neurocognitive disturbances), occurring in both groups and likely related to the underlying 
brain disease. Moderate to severe fatigue was recorded in 8 (3.3%) patients in the RT group 
(grade 2) and 16 (6.8%) in the TMZ group (one reported as grade 3). Thromboembolic 
events were reported in 3 patients (1.2%, 2 in RT, 1 in TMZ arm).
At a median follow-up of 4 years (48 months, (IQR:31–56)), 262 (55%) progression events 
(126/52.5% with RT, 136/57.4% with TMZ) (for details see appendix of supplemental data, 
appendix table S3) and 119 (25%) deaths (63/26.3% with RT, 56/23.6% with TMZ) were 
recorded. The median PFS was 46 months (95 percent confidence interval [CI], 40 to 56) 
with RT alone and 39 months (CI, 35 to 44) with TMZ alone (Figure 2). The unadjusted HR 
for progression was 1.16 for patients treated with TMZ versus RT (CI, 0.9 to 1.5; log-rank 
p=0.22). Adjusted HR were computed (see appendix of supplemental data, appendix table 
S4) and provided the same conclusions without significant differences between groups. With 
only 25% of patients having died to date, no meaningful analyses of OS are possible.
In 407 of the 477 patients (85%) randomized, sufficient material was available for 
successfully assessing the 1p status (stratification factor). Molecular data was missing in 
particular in patients who underwent a stereotactic biopsy only. IDH1 or 2 mutations were 
detected in 327/392 (83%) of the tumors, of which 30 (9.4%) had IDH1 mutations other than 
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the common IDH1-R132H, and 9 (2.8%) were identified in IDH2. Co-deletions of 1p/19q 
(codel) were identified in 117/357 tumors (33%) and the MGMT promoter was methylated 
in 135/150 tumors (90%). The associations of distribution of molecular markers and 
histological glioma subtype (as classified by the local or the two reference pathologists, 
respectively) are shown in the appendix of supplemental data, figure S1. For a representative 
subgroup of 318 patients (for characteristics, see appendix of supplemental data, appendix 
table S5) the IDH mutation status and 1p/19q co-deletion was available: 269 (85%) were 
IDHmt, of which 104 (39%) were IDHmt/codel and 49 (15%) were IDH wild-type (IDHwt). 
These 3 molecular subgroups differed in clinical characteristics, namely age, time between 
initial histological diagnosis and start of treatment, extent of resection and MGMT status 
(table 3), in line with recent reports of several WHO grade II and III glioma datasets.4,24–26 
Interestingly, time from initial surgery/histology to treatment was longer in IDHmt/non-
codel (9.0 months) compared to IDHmt/codel (5.6 months) and IDHwt (3.4 months) (p = 
0.0057). The MGMT promoter status was methylated in all IDHmt/codel (45/45), most but 
not all (86%, 62/72) of the IDHmt/non-codel, and in 56% (5/9) of the IDHwt cases (table 3).
The interaction test showed a significant predictive value of the molecular subtypes for PFS 
in the 318 molecularly characterized patients (table 3, p=0.03). Pairwise analyses revealed a 
favorable prognosis for patients with IDHmt tumors, with a median PFS of 62 months (95% 
CI, 41- upper limit not yet determined) for IDHmt/codel patients; of 48 months (95% CI, 
41–55) for IDHmt/non-codel patients compared to only 20 months (95% CI, 12 −26) for 
IDHwt patients (figure 3). Only patients with IDHmt/non-codel tumors had a longer PFS 
when treated with RT than with TMZ (median PFS 55 months (95% CI, 48 to 66) versus 36 
months (95% CI, 28.4 to 47) translating into a HR of 0.53 (0.35 – 0.82; logrank p= 0.0043) 
(see appendix of supplemental data, appendix table S6). No treatment related differences 
were observed for patients of the other two molecular subgroups (IDHmt/codel and IDHwt 
tumors, respectively).
Discussion
To the best of knowledge, this is the first randomized trial testing the use of chemotherapy 
alone as initial treatment and the first prospective randomized trial in LGG to molecularly 
stratify tumor subgroups before randomization. The study has been designed over 15 years 
ago based on the insights available at that time. Yet, the current analysis includes also 
recently defined molecular markers and subgroups for their prognostic and importantly, also 
predictive value. With a median follow-up of 4 years (IQR:2.6–4.7), there was no significant 
difference in outcome between the two treatment modalities (PFS HR (TMZ vs RT): 1.16, 
95% (0.91–1.48)). Patients with IDHwt tumors had the worst prognosis independent of 
therapy, while patients IDHmt/codel fared best, consistent with other datasets of lower grade 
glioma.4,24–26 Younger age was associated with worse outcome in this trial (table 3). This is 
likely due to molecular subtype dependent differences in age at diagnosis, and age (>40) that 
was one of the criteria for randomization, hence younger patients had to have clinical 
symptoms or unfavorable characteristics to enter the trial (the statistical difference is lost 
after adjustment for molecular subtype, data not shown).
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Nowadays lower grade gliomas (WHO grade II/III) can readily be subclassified into 
prognostic molecular subgroups using an integrative diagnostic approach.21 IDH mutations 
that were discovered after trial implementation are characteristic for LGG and are present in 
over 80%. By today’s understanding, IDHwt tumors may actually belong molecularly to 
other tumor entities, mostly different subtypes of glioblastoma, but also indolent tumors 
such as ganglioglioma, or pilocytic astrocytoma.24,27 Recent retrospective reports suggest 
that among IDHmt gliomas, molecular characterization may be a stronger predictor for 
outcome than tumor grade and other prognostic markers.4,24,26,28 However, the initial 
treatment concept varied and was influenced by the tumor grade; for example in the 
prospective German Glioma Network registry less than 10% of WHO grade II gliomas 
received adjuvant radiotherapy and/or chemotherapy after initial surgery, in contrast to over 
90% of the WHO grade III population.26 Furthermore, the criteria and indication for 
treatment has likely varied over time and between institutions.
For LGG an expectative approach with watchful waiting or surgery when feasible and risk-
adapted adjuvant treatment are commonly the initial management.1 Treatment is initiated 
based on clinical symptoms, patient’s age at presentation, tumor size and radiological 
characteristics as well as tumor growth rate. This leads to a variable time point of treatment 
initiation depending on local practice and judgment, histological tumor characteristics and 
grade may have changed over time, adding to heterogeneity of patient population included. 
In our trial the wide time range from initial histological diagnosis to treatment (1–152 
months, median 6) reflects both the variation in local practice and the heterogeneous natural 
history of the disease. In order to account for the variability between local practice and 
investigators, we stratified patients before randomization according to the treating 
institution. Molecular tumor characterization, correlation with outcome and subsequent 
rational treatment decisions will be of great benefit in individualizing and standardizing 
management of patients with LGG.
We interrogated our data for the predictive value of molecular subgroups. Of note, albeit the 
largest trial ever conducted in this disease, the study was not powered for the molecular 
subgroup analyses. In order to save statistical power, our data were only used to test the 
predictive value of known molecular subgroups and not for identifying new markers. Our 
analyses suggest that primary chemotherapy in patients with IDHmt/non-codel tumors may 
be deleterious; patients treated with TMZ had a significantly shorter PFS. Conversely, PFS 
was comparable between RT and TMZ treated patients in both subgroups of IDHmt/codel, 
and of IDHwt tumors (interaction test p=0.03). However, the IDHwt subgroup is a small 
(n=49), potentially heterogeneous and molecularly ill-defined group of patients.
All IDHmt/codel and 90% of the IDHmt/non-codel tumors have a methylated MGMT 
promoter, this implies that its clinical impact cannot be differentiated from the IDH mutation 
alone, or from its associated CpG island methylator phenotype (CIMP),29 due to the nested 
dependency of these alterations.22 Hence, MGMT testing does not provide additional 
prognostic or predictive value in the IDHmt subgroup. In IDHwt tumors, MGMT may be of 
a predictive value, however the rarity of this constellation in our cohort does not allow for 
formal testing. Nevertheless, other reports by our and other groups in IDHwt grade III 
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gliomas strongly suggest a predictive effect for benefit from chemotherapy for patients with 
a methylated MGMT status.30,31
Accurate molecular prognostication is of particular importance in a disease with such a 
highly variable outcome. While intensive therapy is warranted for rapidly progressive 
tumors, acute and long-term toxicity and deficits may impair quality of life and neurological 
function in patients with indolent tumors.32–34 Quality of life and MMSE are reported in 
detail separately.35 The median PFS with RT alone in our trial is 46 months, comparable to 
the 48 months reported for the RT only arm of the randomized RTOG98-02 trial.8 In that 
trial, patients were randomized between RT alone, or RT followed by adjuvant PCV-
chemotherapy (procarbazine, lomustine [CCNU], vincristine). Recently, and only after a 
long-term follow-up (12 years) the RTOG98-02 trial demonstrates a survival benefit (HR 
0.59, p=0.003) favoring adjuvant chemotherapy,8 almost exclusively in patients with 
oligodendroglioma, the subtype that commonly harbors the 1p/19q co-deletion. However, 
RTOG98-02 and our trial are not readily comparable; the median age in RTOG98-02 was 4 
years younger (median 40/41 years, treatment arms vs 44/45 years, this trial), the 
distribution of the histologic subtypes was different, and molecular subgroup analyses for 
1p/19q codel are not available in RTOG98-02.8 The high interobserver difference even 
among expert neuropathologists observed in our and other studies precludes reliable 
comparisons at present. Whether combined modality therapy should be used for initial 
treatment of LGG was not addressed by our trial as we were aiming at minimizing the 
potential risk of late toxicity in a patient population that may live for > 10–20 years.
Our trial also identified molecular subgroups (IDHwt or IDHmt/non-codel tumors) that carry 
a clearly inferior prognosis. Here novel or more intensive treatment strategies are warranted 
even at the price of some toxicity, while the optimal treatment strategy for favorable-
prognosis patients with IDHmt/codel tumors remains controversial. Our results failed to 
demonstrate improvement of PFS when treating patients upfront with chemotherapy alone, 
but substituting irradiation by equally effective TMZ chemotherapy may prevent or delay 
from long-term radiation-induced side effects. In the German NOA04-trial in patients with 
anaplastic glioma the treatment sequence (chemo first →RT at progression or vice versa) did 
not matter with regards to overall survival.36 Long-term follow-up of EORTC and RTOG 
trials on anaplastic (WHO grade III) glioma suggests an improved outcome for patients with 
1p/19q codel tumors treated with radiotherapy and early adjuvant chemotherapy.37,38
We set out to evaluate a well-tolerated and at the time of trial initiation novel alkylating 
agent as primary treatment for LGG. Still, there are some inherent limitations to our trial. 
The primary endpoint is progression-free survival, thus dependent on imaging technique, 
methodology of tumor assessment and the frequency of imaging.39 Observer experience and 
potential imaging changes induced by radiotherapy that would be absent in the 
chemotherapy arm may be further confounding factors. In the most favorable subgroups, 
patients in either arm may not yet have experienced tumor progression, and data is thus still 
somewhat immature. The striking differences in outcome for the distinct molecular 
subgroups underline the need for integration of the molecular markers into tumor diagnosis 
for future treatment stratification. Based on our results, the search for IDH mutation as well 
as 1p/19q deletion should be part of the initial diagnostic workup for all patients with low-
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grade glioma as now implemented in the updated WHO classification 2016,40 while the 
MGMT promoter methylation status may have an added value only in IDHwt tumors. Our 
trial contributes to molecularly defining the individual therapeutic strategy, intensive 
treatments for poor-prognosis patients while avoiding overtreatment in indolent disease. 
While recent mature results and subgroup analyses from a randomized trial conducted in the 
1990’s demonstrates a superior outcome with radiotherapy followed by chemotherapy both 
in grade II and grade III glioma, our results may support the option of initial chemotherapy 
alone in good-prognosis IDHmt and codeleted tumors.8,41 Only very long-term follow-up 
will determine the role of single modality chemotherapy in patients with chemotherapy-
sensitive disease.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
Consort statement. The numbers of patients registered, eligibility and allocation per 
treatment arms, including reasons for exclusion per treatment arm. At the date of database 
lock, 51 registered patients did not meet the criteria to be eligible for randomization.
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Figure 2. 
Progression-free survival per treatment group. The difference between per log rank test was 
not significant (HR: 1.16; 95 percent confidence interval, 0.9 to 1.5; P=0.22).
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Figure 3. 
Molecular subgroups, PFS and treatment. Kaplan-Meier curves are shown for the 3 
molecular subgroups, IDH mutated and 1p/19q co-deleted (IDHmt/codel), IDHmt/non-
codel, and IDH wild-type (IDHwt). (A) prognostic value of the molecular subgroups is 
observed. Pairwise comparisons of the two treatment arms RT and TMZ are shown by 
molecular subtype: IDHmt/non-codel (B), IDHmt/codel (C), and IDHwt (D).
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Table 1
Baseline characteristics
RT
N=240 (%)
TMZ
N=237 (%)
Total
N=477 (%)
Age [yrs], median (range) 44 (18–72) 45 (19–75) 45 (18–75)
< 40 92 (38) 85 (36) 177 (37.1)
>= 40 148 (62) 152 (64) 300 (62.9)
Sex
Male 138 (58) 137 (58) 275 (58)
Female 102 (43) 100 (42) 202 (42)
WHO Performance Status
0 151 (63) 143 (60) 294 (62)
1 79 (33) 86 (36) 165 (35)
2 10 (4) 8 (3) 18 (4)
RTOG Neurologic Function
Status
0 126 (53) 127 (54) 253 (53)
1 90 (38) 82 (35) 172 (36)
2 17 (7) 22 (9) 39 (8)
3 7 (3) 6 (3) 13 (3)
Contrast enhancement on MRI
No 119 (50) 119 (50) 238 (50)
Yes 121 (50) 118 (50) 239 (50)
Initial resection status (by
investigator)
Biopsy 96 (40) 93 (39) 189 (40)
Partial removal 106 (44) 100 (42) 206 (43)
Total removal 37 (15.4) 44 (18.6) 81 (17)
Missing 1(<1) 0(0) 1 (<1)
Time between last biopsy or surgery and treatment start (months) a
Median (range) 4.8 (0.8–116.6) 4.8 (0–151.5) 4.8 (0–151.5)
Time between first histological diagnosis and treatment start (months) a
Median (range) 5.2 (0.7–124.6) 5.9 (0.9–151.5) 5.6 (0.7–151.5)
Reason for treatmentb
Refractory seizuresc
No 210 (88) 202 (85) 412 (86)
Yes 28 (12) 34 (14) 62 (13)
Radiological progression
No 90 (38) 83 (35) 173 (36)
Yes 148 (62) 154 (65) 302 (63)
New/worsening symptoms other
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RT
N=240 (%)
TMZ
N=237 (%)
Total
N=477 (%)
than seizures
No 183 (76) 187 (79) 370 (78)
Yes 55 (23) 49 (21) 104 (22)
Tumor involving midline
No 173 (72) 186 (79) 359 (75)
Midline shift 29 (12) 23 (10) 52 (11)
Midline infiltration 24 (10) 20 (8) 44 (9)
Both 10 (4) 8 (3) 18 (4)
Histology (local pathology)
Astrocytoma WHO II 88 (37) 79 (33) 167 (35)
Oligoastrocytoma WHO II 58 (24) 60 (25) 118 (25)
Oligodendroglioma WHO II 94 (39) 98 (41) 192 (40)
Histology (central review)d
*LGG confirmed 227 (95) 211 (89) 438 (92)
**LGG not confirmed 8(3) 12 (5) 20 (4)
Missing review 5 (2) 14 (6) 19 (4)
Molecular markers
1p
1p deleted 98 (41) 97 (41) 195 (41)
1p normal 107 (45) 106 (45) 213 (45)
Missing 35 (15) 34 (14) 69 (15)
1p/19q status
1p/19q co-deleted 55 (23) 62 (26) 117 (25)
1p/19q non-co-deleted 125 (52) 115 (49) 240 (50)
Missing 60 (25) 60 (25) 120(25)
IDH 1/2 mutation status
IDH 1/2 mutated 164 (68) 163 (69) 327 (69)
IDH 1/2 wild-type 35 (15) 30 (13) 65 (14)
Undetermined 41 (17) 44 (19) 85 (18)
MGMT status
MGMT unmethylated 6 (3) 9 (4) 15 (33)
MGMT methylated 72 (30) 63 (27) 135 (28)
Missing 162 (68) 165 (70) 327 (69)
a
For patients who did not start randomized treatment, date of randomization was used.
b
Multiple mention/reasons
c
Refractory seizures defined as: Suffering from persistent seizures, defined as having both: persistent seizures interfering with every day life 
activities other than driving a car and failed three lines of anti-epileptic drug regimen including at least one combination regimen
d
* agreement with at least one of the central reviewers
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** discordance mainly glioma grade III
Stratification factors:
• WHO Performance Status: a performance status of 0 denotes asymptomatic, 1 symptomatic and fully ambulatory, and 2 
symptomatic and in bed less than 50 % of the day.
• RTOG NFS: a neurologic functions status of 0 denotes asymptomatic, a status of 1 minor neurologic symptoms, 2 moderate 
symptomatic, ambulatory with assistance, 3 moderate symptomatic; not fully ambulatory and requires assistance, 4 severely 
symptomatic; complete assistance at home or in institution-unable to work.
Lancet Oncol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Baumert et al. Page 25
Ta
bl
e 
2
To
x
ic
ity
 a
nd
 tr
ea
tm
en
t e
m
er
gi
ng
 a
dv
er
se
 e
v
en
ts
 [T
EA
E]
R
T
TM
Z
(N
=2
28
)
(N
=2
35
)
H
em
at
ol
og
ic
al
 to
xi
ci
ty
, 
N
(%
)
G
r1
–2
G
r3
G
r4
G
r1
–2
G
r3
G
r4
Le
uk
o
pe
ni
a
12
(5.
3)
12
0(5
1.1
)
8(3
.4)
1(0
.4)
N
eu
tro
pe
ni
a
6(2
.6)
1(0
.4)
80
(34
)
6(2
.6)
4(1
.7)
Th
ro
m
bo
cy
to
pe
ni
a
8(3
.4)
4(1
.7)
7(3
.0)
A
ne
m
ia
7(3
.1)
58
(24
.7)
1(0
.4)
1(0
.4)
O
th
er
 T
EA
E,
 N
(%
)
A
lle
rg
y/
Im
m
un
ol
og
y
3(1
.3)
11
(4.
7)
1(0
.4)
A
ud
ito
ry
/e
ar
37
(16
.2)
4(1
.8)
35
(14
.9)
1(0
.4)
Ca
rd
ia
c(g
en
era
l)
10
(4.
4)
11
(4.
7)
2(0
.9)
Co
ns
tit
ut
io
na
l s
ym
pt
om
s
14
1(6
1.8
)
8(3
.5)
15
9(6
7.7
)
15
(6.
4)
1(0
.4)
D
er
m
at
ol
og
y/
sk
in
11
2(4
9.1
)
73
(31
.1)
4(1
.7)
En
do
cr
in
e
9(3
.9)
12
(5.
1)
G
as
tro
in
te
sti
na
l
66
(28
.9)
4(1
.8)
15
8(6
7.2
)
10
(4.
3)
H
em
or
rh
ag
e/
bl
ee
di
ng
8(3
.4)
H
ep
at
ob
ili
ar
/p
an
cr
ea
s
2(0
.9)
In
fe
ct
io
n
23
(10
.1)
2(0
.9)
66
(28
.1)
7(3
.0)
1(0
.4)
Ly
m
ph
at
ic
s
1(0
.4)
1(0
.4)
9(3
.8)
M
et
ab
ol
ic
/la
bo
ra
to
ry
1(0
.4)
2(0
.9)
4(1
.7)
M
us
cu
lo
sk
el
et
al
/so
ft 
tis
su
e
20
(8.
8)
2(0
.9)
21
(8.
9)
2(0
.9)
N
eu
ro
lo
gy
13
4(5
8.8
)
25
(11
.0)
3(1
.3)
12
5(5
3.2
)
36
(15
.3)
5(2
.1)
O
cu
la
r/v
isu
al
36
(15
.8)
46
(19
.6)
Pa
in
10
7(4
6.9
)
6(2
.6)
12
1(5
1.5
)
7(3
.0)
Pu
lm
on
ar
y/
up
pe
r r
es
pi
ra
to
ry
13
(5.
7)
1(0
.4)
42
(17
.9)
1(0
.4)
R
en
al
/g
en
ito
ur
in
ar
y
4(1
.8)
2(0
.9)
16
(6.
8)
Se
co
nd
ar
y 
m
al
ig
na
nc
y
1(0
.4)
1(0
.4)
4(1
.7)
Se
x
u
al
/re
pr
od
uc
tiv
e 
fu
nc
tio
n
7(3
.1)
11
(4.
7)
4(1
.7)
Lancet Oncol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Baumert et al. Page 26
R
T
TM
Z
(N
=2
28
)
(N
=2
35
)
H
em
at
ol
og
ic
al
 to
xi
ci
ty
, 
N
(%
)
G
r1
–2
G
r3
G
r4
G
r1
–2
G
r3
G
r4
Su
rg
er
y/
in
tra
-o
pe
ra
tiv
e 
in
jur
y
2(0
.9)
Sy
nd
ro
m
es
 (f
lu-
lik
e,
 s
o
m
n
o
le
nc
e)
3(1
.3)
12
(5.
1)
Va
sc
u
la
r
2(0
.9)
1(0
.4)
1(0
.4)
1(0
.4)
A
n 
in
di
v
id
ua
l p
at
ie
nt
 m
ay
 h
av
e 
ex
pe
rie
nc
ed
 d
iv
er
se
 a
n
d 
m
ul
tip
le
 to
xi
ci
tie
s, 
th
us
 th
e 
nu
m
be
r o
f p
at
ie
nt
s a
ffe
ct
ed
 b
y 
to
xi
ci
ty
 is
 lo
w
er
.
Lancet Oncol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Baumert et al. Page 27
Ta
bl
e 
3
M
ol
ec
ul
ar
 su
bt
yp
es
: C
lin
ic
al
 p
ar
am
et
er
s a
nd
 o
ut
co
m
e
ID
H
m
t/c
od
el
(n
 = 
10
4)
ID
H
m
t/n
on
-c
od
el
(n
 = 
16
5)
ID
H
wt
(n
 = 
49
)
To
ta
l
(n
=3
18
)†
p-
va
lu
es
M
ed
ia
n 
ag
e 
at
di
ag
no
sis
 (r
an
ge
)
47
 (2
2–
69
)
41
 (2
0–
69
)
52
 (1
8–
75
)
45
 (1
8–
75
)
0.
00
01
A
ge
 [y
rs
] <
40
25
 (2
4%
)
80
 (4
8%
)
10
 (2
0%
)
11
5 
(36
%)
0.
00
01
A
ge
 [y
rs
] >
=4
0
79
 (7
6%
)
85
 (5
2%
)
39
(80
%)
20
3(6
4%
)
Ti
m
e 
be
tw
ee
n 
la
st
 b
io
ps
y 
or
 su
rg
er
y 
an
d 
tr
ea
tm
en
t s
ta
rt
 (m
on
th
s)$
M
ed
ia
n 
(ra
ng
e)
4.
5 
(1.
2–
89
.5)
5.
5 
(0.
0–
13
6.1
)
3.
4 
(1.
0–
78
.7)
4.
4 
(0.
0–
13
6.1
)
0.
07
Ti
m
e 
be
tw
ee
n 
fir
st
 h
ist
ol
og
ic
al
 d
ia
gn
os
is 
an
d 
tr
ea
tm
en
t s
ta
rt
 (m
on
th
s)$
M
ed
ia
n 
(ra
ng
e)
5.
6 
(1.
0–
12
4.6
)
9.
0 
(1.
3–
13
6.0
)
3.
4 
(1.
0–
78
.7)
5.
6 
(1.
0–
13
6.0
)
0.
00
6
Ex
te
nt
 o
f r
es
ec
tio
n
B
io
ps
y
37
 (3
6%
)
44
 (2
7%
)
32
 (6
5%
)
11
3 
(36
%)
<
0.
00
01
Pa
rt
ia
l r
em
ov
al
51
 (4
9%
)
86
 (5
2%
)
11
 (2
2%
)
14
8 
(47
%)
To
ta
l r
em
ov
al
16
 (1
5%
)
34
 (2
1%
)
6 
(12
%)
56
 (1
8%
)
M
iss
in
g
0 
(0%
)
1 
(<
1%
)
0 
(0%
)
1 
(<
1%
)
Fe
m
a
le
/M
al
e
39
 / 
65
 (3
7%
)
74
 / 
91
 (4
5%
)
21
 / 
28
 (4
3%
)
13
4/
18
4 
(42
%)
0.
50
*
M
G
M
TS
TP
27
m
et
h
(n=
45
)
(n=
72
)
(n=
9)
(n=
12
6)
 
 
 
U
nm
et
hy
la
te
d
0 
(0%
)
10
 (1
4%
)
4 
(44
%)
14
 (1
1%
)
0.
00
03
 
 
 
M
et
hy
la
te
d
45
 (1
00
%)
62
 (8
6%
)
5 
(56
%)
11
2 
(89
%)
M
ed
ia
n 
Pr
o
gr
es
sio
n 
Fr
ee
 S
ur
v
iv
a
l, 
m
on
th
s (
95
%
 C
I)
In
te
ra
ct
io
n
te
st
p=
0.
03
TM
Z
55
.0
3 
(37
.95
, N
)
36
.0
1 
(28
.42
,
46
.9
5)
23
.6
9 
(5.
55
,
42
.2
5)
40
.4
8 
(35
.25
,
46
.9
5)
R
T
61
.6
3 
(42
.32
, N
)
55
.3
6 
(47
.87
,
65
.8
7)
19
.0
9 
(11
.27
,
25
.6
9)
50
.9
9 
(39
.79
,
61
.6
3)
Pr
o
gr
es
sio
n 
Fr
ee
 S
ur
v
iv
a
l a
t 5
 y
ea
rs
, 
%
 (9
5%
 C
I)
TM
Z
47
.3
9(3
0.7
1,
62
.3
5)
19
.4
3(8
.87
, 3
3.0
0)
17
.7
8(3
.69
,
40
.4
8)
28
.9
2(1
9.7
8,
38
.6
9)
R
T
58
.4
9(3
9.4
3,
73
.4
1)
42
.5
0(2
7.3
8,
56
.8
3)
0.
00
(0.
00
, 0
.00
)
40
.1
8(2
9.9
4,
50
.1
9)
H
az
ar
d 
ra
tio
Lancet Oncol. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Baumert et al. Page 28
ID
H
m
t/c
od
el
(n
 = 
10
4)
ID
H
m
t/n
on
-c
od
el
(n
 = 
16
5)
ID
H
wt
(n
 = 
49
)
To
ta
l
(n
=3
18
)†
p-
va
lu
es
TM
Z 
vs
 R
T
1.
04
 (0
.56
,
1.
93
)
1.
86
 (1
.21
, 2
.87
)
0.
67
 (0
.34
, 1
.32
)
1.
18
 (0
.87
,
1.
60
)
p-
va
lu
es
p=
0.
91
p=
0.
00
4
p=
0.
24
p=
0.
30
*
Te
st
 o
nl
y 
av
ai
la
bl
e 
fo
r a
 su
bg
ro
up
.
$ F
o
r 
pa
tie
nt
s w
ho
 d
id
 n
ot
 st
ar
t r
an
do
m
iz
ed
 tr
ea
tm
en
t, 
da
te
 o
f r
an
do
m
iz
at
io
n 
w
as
 u
se
d.
 N
 is
 fo
r m
ed
ia
n 
no
t r
ea
ch
ed
.
† S
ub
gr
ou
p 
re
pr
es
en
ta
tiv
e 
o
f t
he
 o
v
er
al
l p
op
ul
at
io
n 
w
ith
 re
sp
ec
t t
o 
ba
se
lin
e 
ch
ar
ac
te
ris
tic
s (
ex
ce
pt
 fo
r t
he
 m
or
e 
fre
qu
en
t d
eb
u
lk
in
g 
su
rg
er
y) 
an
d o
v
er
al
l o
ut
co
m
e 
(P
FS
).
Lancet Oncol. Author manuscript; available in PMC 2017 November 01.
